Heron Therapeutics (HRTX) Stock Forecast, Price Target & Predictions
HRTX Stock Forecast
Heron Therapeutics stock forecast is as follows: an average price target of $7.00 (represents a 343.04% upside from HRTX’s last price of $1.58) and a rating consensus of 'Buy', based on 2 wall street analysts offering a 1-year stock forecast.
HRTX Price Target
The average price target for Heron Therapeutics (HRTX) is $7.00 based on 1-year price targets from 2 Wall Street analysts in the past 3 months, with a price target range of $9.00 to $5.00. This represents a potential 343.04% upside from HRTX's last price of $1.58.
HRTX Analyst Ratings
According to 2 Wall Street analysts, Heron Therapeutics's rating consensus is 'Buy'. The analyst rating breakdown for HRTX stock is 0 'Strong Buy' (0.00%), 2 'Buy' (100.00%), 0 'Hold' (0.00%), 0 'Sell' (0.00%), and 0 'Strong Sell' (0.00%).
Heron Therapeutics Price Target by Analyst
| Date | Analyst | Company | Price Target | Price when Published | Price Target/Price when Published | Price Target/Last Closing Price |
|---|---|---|---|---|---|---|
| May 16, 2024 | Carl Byrnes | Northland Securities | $9.00 | $3.22 | 179.50% | 469.62% |
| Mar 13, 2024 | Serge Belanger | Needham | $5.00 | $3.01 | 66.11% | 216.46% |
The latest Heron Therapeutics stock forecast, released on May 16, 2024 by Carl Byrnes from Northland Securities, set a price target of $9.00, which represents a 179.50% increase from the stock price at the time of the forecast ($3.22), and a 469.62% increase from HRTX last price ($1.58).
Heron Therapeutics Price Target by Period
| 1M | 3M | 12M | |
|---|---|---|---|
| # Anlaysts | - | - | 2 |
| Avg Price Target | - | - | $7.00 |
| Last Closing Price | $1.58 | $1.58 | $1.58 |
| Upside/Downside | -100.00% | -100.00% | 343.04% |
In the current month, the average price target of Heron Therapeutics stock is -, according to 0 Wall Street analyst offering twelve months forecast. The average price target represents a -100.00% decrease as opposed to Heron Therapeutics's last price of $1.58. This month's average price target is down NaN% compared to last quarter, and down -100.00% compared to last year.
Analyst Ratings Upgrades/Downgrades
| Date | Company | Previous Rating | New Rating | Rating Change |
|---|---|---|---|---|
| Jun 12, 2024 | Rodman & Renshaw | Buy | Initialise | |
| Mar 13, 2024 | Needham | Buy | Buy | Hold |
| Nov 15, 2023 | Needham | Buy | Buy | Hold |
Heron Therapeutics's last stock rating was published by Rodman & Renshaw on Jun 12, 2024. The company Initialise its HRTX rating from "null" to "Buy".
Heron Therapeutics Financial Forecast
Heron Therapeutics Revenue Forecast
| Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | Jun 19 | Mar 19 | Mar 18 | Mar 17 | Mar 09 | Mar 08 | Jun 07 | Mar 04 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | $34.23M | $31.43M | - | $29.61M | $30.03M | $26.56M | $27.63M | $23.46M | $21.49M | $23.23M | $22.44M | $20.02M | $20.61M | $19.96M | $22.67M | $25.40M | $35.08M | $42.62M | $36.66M | $31.60M | $11.57M | $3.63M | $8.00K | - | - | - |
| Avg Forecast | $37.29M | $36.77M | $36.09M | $32.98M | $31.23M | $32.65M | $31.70M | $29.69M | $27.24M | $26.96M | $24.55M | $22.61M | $25.77M | $25.52M | $29.45M | $25.71M | $19.55M | $17.17M | $19.81M | $20.09M | $31.81M | $34.55M | $31.43M | $28.04M | $12.28M | $3.30M | $10.00K | $127.05K | $538.95K | $590.00K |
| High Forecast | $37.74M | $36.84M | $36.89M | $32.98M | $31.95M | $32.70M | $32.40M | $30.35M | $27.85M | $26.96M | $24.55M | $22.61M | $25.77M | $25.52M | $29.45M | $25.71M | $19.55M | $17.17M | $19.81M | $20.09M | $31.81M | $34.55M | $31.43M | $28.04M | $14.74M | $3.96M | $12.00K | $152.45K | $646.74K | $708.00K |
| Low Forecast | $36.83M | $36.69M | $35.25M | $32.98M | $30.49M | $32.60M | $30.96M | $29.00M | $26.61M | $26.96M | $24.55M | $22.61M | $25.77M | $25.52M | $29.45M | $25.71M | $19.55M | $17.17M | $19.81M | $20.09M | $31.81M | $34.55M | $31.43M | $28.04M | $9.83M | $2.64M | $8.00K | $101.64K | $431.16K | $472.00K |
| # Analysts | 2 | 1 | 1 | 1 | 2 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 13 | 8 | 8 | 9 | 12 | 7 | 7 | 8 | 16 | 20 | 11 | 18 | 18 | 11 |
| Surprise % | - | - | - | - | 1.10% | 0.96% | - | 1.00% | 1.10% | 0.99% | 1.13% | 1.04% | 0.83% | 0.91% | 0.76% | 0.78% | 1.05% | 1.16% | 1.14% | 1.26% | 1.10% | 1.23% | 1.17% | 1.13% | 0.94% | 1.10% | 0.80% | - | - | - |
Heron Therapeutics's average Quarter revenue forecast for Mar 24 based on 1 analysts is $32.98M, with a low forecast of $32.98M, and a high forecast of $32.98M. HRTX's average Quarter revenue forecast represents a -3.66% decrease compared to the company's last Quarter revenue of $34.23M (Dec 23).
Heron Therapeutics EBITDA Forecast
| Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | Jun 19 | Mar 19 | Mar 18 | Mar 17 | Mar 09 | Mar 08 | Jun 07 | Mar 04 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 2 | 1 | 1 | 1 | 2 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 13 | 8 | 8 | 9 | 12 | 7 | 7 | 8 | 16 | 20 | 11 | 18 | 18 | 11 |
| EBITDA | - | - | - | - | $-9.51M | $-24.20M | - | $-32.34M | $-20.36M | $-41.18M | $-48.83M | $-62.20M | $-56.26M | $-51.65M | $-60.28M | $-51.88M | $-61.57M | $-57.46M | $-54.45M | $-50.96M | $-57.36M | $-33.07M | $-49.73M | $-62.55M | $-51.88M | $-48.97M | $-2.87M | - | - | - |
| Avg Forecast | $-35.92M | $-35.42M | $-34.77M | $-69.49M | $-30.08M | $-31.45M | $-30.54M | $-54.94M | $-66.16M | $-26.14M | $-23.80M | $-43.43M | $-24.99M | $-24.75M | $-28.55M | $-50.96M | $-18.95M | $-16.65M | $-19.21M | $-57.23M | $-30.85M | $-33.50M | $-30.47M | $-25.27M | $-54.90M | $-44.13M | $-2.87M | $-6.59M | $-2.03M | $-2.81M |
| High Forecast | $-35.49M | $-35.35M | $-33.96M | $-55.59M | $-29.37M | $-31.41M | $-29.83M | $-43.95M | $-52.93M | $-26.14M | $-23.80M | $-34.74M | $-24.99M | $-24.75M | $-28.55M | $-40.77M | $-18.95M | $-16.65M | $-19.21M | $-45.78M | $-30.85M | $-33.50M | $-30.47M | $-20.22M | $-43.92M | $-35.30M | $-2.29M | $-5.27M | $-1.63M | $-2.24M |
| Low Forecast | $-36.36M | $-35.49M | $-35.54M | $-83.39M | $-30.78M | $-31.50M | $-31.22M | $-65.92M | $-79.39M | $-26.14M | $-23.80M | $-52.11M | $-24.99M | $-24.75M | $-28.55M | $-61.16M | $-18.95M | $-16.65M | $-19.21M | $-68.68M | $-30.85M | $-33.50M | $-30.47M | $-30.33M | $-65.88M | $-52.95M | $-3.44M | $-7.91M | $-2.44M | $-3.37M |
| Surprise % | - | - | - | - | 0.32% | 0.77% | - | 0.59% | 0.31% | 1.58% | 2.05% | 1.43% | 2.25% | 2.09% | 2.11% | 1.02% | 3.25% | 3.45% | 2.83% | 0.89% | 1.86% | 0.99% | 1.63% | 2.47% | 0.95% | 1.11% | 1.00% | - | - | - |
undefined analysts predict HRTX's average Quarter EBITDA for undefined to be $NaN, with a high of $NaN and a low of $NaN. This is NaN% lower than Heron Therapeutics's previous annual EBITDA (undefined) of $NaN.
Heron Therapeutics Net Income Forecast
| Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | Jun 19 | Mar 19 | Mar 18 | Mar 17 | Mar 09 | Mar 08 | Jun 07 | Mar 04 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 2 | 1 | 1 | 1 | 2 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 13 | 8 | 8 | 9 | 12 | 7 | 7 | 8 | 16 | 20 | 11 | 18 | 18 | 11 |
| Net Income | - | - | - | - | $-10.72M | $-25.01M | - | $-32.47M | $-27.21M | $-41.93M | $-63.22M | $-64.85M | $-52.24M | $-52.41M | $-61.02M | $-52.61M | $-62.28M | $-58.23M | $-55.19M | $-51.58M | $-57.92M | $-33.59M | $-50.22M | $-63.01M | $-52.27M | $-50.33M | $-2.96M | - | - | - |
| Avg Forecast | $-4.67M | $-5.79M | $-6.01M | $-70.29M | $-23.51M | $-44.70M | $-34.13M | $-55.56M | $-64.26M | $-57.27M | $-81.64M | $-43.92M | $-87.83M | $-92.60M | $-84.99M | $-51.69M | $-98.43M | $-95.52M | $-94.65M | $-57.93M | $-84.95M | $-86.81M | $-93.21M | $-25.46M | $-55.30M | $-45.35M | $-2.96M | $-6.68M | $-2.72M | $-2.86M |
| High Forecast | $-4.53M | $-5.61M | $-5.83M | $-56.23M | $-20.38M | $-43.35M | $-33.10M | $-44.45M | $-51.40M | $-57.27M | $-81.64M | $-35.14M | $-87.83M | $-92.60M | $-84.99M | $-41.35M | $-98.43M | $-95.52M | $-94.65M | $-46.34M | $-84.95M | $-86.81M | $-93.21M | $-20.37M | $-44.24M | $-36.28M | $-2.37M | $-5.35M | $-2.18M | $-2.29M |
| Low Forecast | $-4.80M | $-5.96M | $-6.18M | $-84.34M | $-26.64M | $-46.00M | $-35.12M | $-66.68M | $-77.11M | $-57.27M | $-81.64M | $-52.71M | $-87.83M | $-92.60M | $-84.99M | $-62.03M | $-98.43M | $-95.52M | $-94.65M | $-69.51M | $-84.95M | $-86.81M | $-93.21M | $-30.55M | $-66.36M | $-54.42M | $-3.55M | $-8.02M | $-3.27M | $-3.43M |
| Surprise % | - | - | - | - | 0.46% | 0.56% | - | 0.58% | 0.42% | 0.73% | 0.77% | 1.48% | 0.59% | 0.57% | 0.72% | 1.02% | 0.63% | 0.61% | 0.58% | 0.89% | 0.68% | 0.39% | 0.54% | 2.47% | 0.95% | 1.11% | 1.00% | - | - | - |
Heron Therapeutics's average Quarter net income forecast for undefined is $NaN, with a range of $NaN to $NaN. HRTX's average Quarter net income forecast represents a NaN% decrease compared to the company's last Quarter net income of $NaN (undefined).
Heron Therapeutics SG&A Forecast
| Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | Jun 19 | Mar 19 | Mar 18 | Mar 17 | Mar 09 | Mar 08 | Jun 07 | Mar 04 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 2 | 1 | 1 | 1 | 2 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 13 | 8 | 8 | 9 | 12 | 7 | 7 | 8 | 16 | 20 | 11 | 18 | 18 | 11 |
| SG&A | - | - | - | - | $23.62M | $24.60M | - | $32.01M | $26.70M | $28.18M | $32.12M | $32.95M | $34.37M | $34.99M | $33.16M | $24.81M | $28.06M | $22.00M | $25.41M | $30.62M | $30.29M | $25.57M | $33.42M | $38.37M | $20.86M | $18.36M | $927.00K | - | - | - |
| Avg Forecast | $41.60M | $41.02M | $40.26M | $36.79M | $34.84M | $36.43M | $35.36M | $28.66M | $30.39M | $30.08M | $27.39M | $25.22M | $28.75M | $28.48M | $32.86M | $24.37M | $21.81M | $19.15M | $22.10M | $22.42M | $35.49M | $38.55M | $35.06M | $15.50M | $13.70M | $3.69M | $11.16K | $141.74K | $601.28K | $658.24K |
| High Forecast | $42.11M | $41.10M | $41.16M | $36.79M | $35.65M | $36.48M | $36.15M | $34.39M | $31.07M | $30.08M | $27.39M | $25.22M | $28.75M | $28.48M | $32.86M | $29.25M | $21.81M | $19.15M | $22.10M | $22.42M | $35.49M | $38.55M | $35.06M | $18.60M | $16.45M | $4.42M | $13.39K | $170.09K | $721.53K | $789.89K |
| Low Forecast | $41.10M | $40.94M | $39.33M | $36.79M | $34.02M | $36.37M | $34.54M | $22.93M | $29.68M | $30.08M | $27.39M | $25.22M | $28.75M | $28.48M | $32.86M | $19.50M | $21.81M | $19.15M | $22.10M | $22.42M | $35.49M | $38.55M | $35.06M | $12.40M | $10.96M | $2.95M | $8.93K | $113.39K | $481.02K | $526.59K |
| Surprise % | - | - | - | - | 0.68% | 0.68% | - | 1.12% | 0.88% | 0.94% | 1.17% | 1.31% | 1.20% | 1.23% | 1.01% | 1.02% | 1.29% | 1.15% | 1.15% | 1.37% | 0.85% | 0.66% | 0.95% | 2.47% | 1.52% | 4.98% | 83.09% | - | - | - |
Heron Therapeutics's average Quarter SG&A projection for Mar 24 is $36.79M, based on 1 Wall Street analysts, with a range of $36.79M to $36.79M. The forecast indicates a 55.79% rise compared to HRTX last annual SG&A of $23.62M (Dec 23).
Heron Therapeutics EPS Forecast
| Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | Jun 19 | Mar 19 | Mar 18 | Mar 17 | Mar 09 | Mar 08 | Jun 07 | Mar 04 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 2 | 1 | 1 | 1 | 2 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 13 | 8 | 8 | 9 | 12 | 7 | 7 | 8 | 16 | 20 | 11 | 18 | 18 | 11 |
| EPS | - | - | - | - | $-0.07 | $-0.17 | - | $-0.27 | $-0.23 | $-0.38 | $-0.62 | $-0.64 | $-0.51 | $-0.51 | $-0.62 | $-0.58 | $-0.68 | $-0.64 | $-0.61 | $-0.57 | $-0.65 | $-0.42 | $-0.63 | $-0.80 | $-0.81 | $-1.00 | $-2.00 | - | - | - |
| Avg Forecast | $-0.03 | $-0.04 | $-0.04 | $-0.07 | $-0.15 | $-0.29 | $-0.22 | $-0.22 | $-0.32 | $-0.38 | $-0.54 | $-0.48 | $-0.58 | $-0.61 | $-0.56 | $-0.54 | $-0.65 | $-0.63 | $-0.62 | $-0.65 | $-0.56 | $-0.57 | $-0.61 | $-0.49 | $-0.91 | $-0.82 | $-2.00 | $-4.20 | $-19.62 | $-5.28 |
| High Forecast | $-0.03 | $-0.04 | $-0.04 | $-0.07 | $-0.13 | $-0.28 | $-0.22 | $-0.21 | $-0.31 | $-0.38 | $-0.54 | $-0.48 | $-0.58 | $-0.61 | $-0.56 | $-0.54 | $-0.65 | $-0.63 | $-0.62 | $-0.65 | $-0.56 | $-0.57 | $-0.61 | $-0.49 | $-0.73 | $-0.66 | $-1.60 | $-3.36 | $-15.70 | $-4.22 |
| Low Forecast | $-0.03 | $-0.04 | $-0.04 | $-0.08 | $-0.17 | $-0.30 | $-0.23 | $-0.22 | $-0.33 | $-0.38 | $-0.54 | $-0.48 | $-0.58 | $-0.61 | $-0.56 | $-0.54 | $-0.65 | $-0.63 | $-0.62 | $-0.65 | $-0.56 | $-0.57 | $-0.61 | $-0.49 | $-1.09 | $-0.98 | $-2.40 | $-5.04 | $-23.54 | $-6.34 |
| Surprise % | - | - | - | - | 0.46% | 0.58% | - | 1.25% | 0.73% | 1.01% | 1.16% | 1.32% | 0.88% | 0.84% | 1.11% | 1.07% | 1.05% | 1.02% | 0.98% | 0.87% | 1.17% | 0.74% | 1.03% | 1.64% | 0.89% | 1.22% | 1.00% | - | - | - |
According to undefined Wall Street analysts, Heron Therapeutics's projected average Quarter EPS for undefined is $NaN, with a low estimate of $NaN and a high estimate of $NaN. This represents a NaN% decrease compared to HRTX previous annual EPS of $NaN (undefined).
Heron Therapeutics Peer Comparison by Price Target
| Ticker | Company | Last Closing Price | Avg Price Target | Upside/Downside | Avg Rating |
|---|---|---|---|---|---|
| INZY | Inozyme Pharma | $2.94 | $16.00 | 444.22% | Buy |
| XFOR | X4 Pharmaceuticals | $0.74 | $3.67 | 395.95% | Buy |
| PDSB | PDS Bio | $1.96 | $9.00 | 359.18% | Buy |
| HRTX | Heron Therapeutics | $1.65 | $7.00 | 324.24% | Buy |
| ABOS | Acumen Pharmaceuticals | $1.96 | $7.00 | 257.14% | Buy |
| TERN | Terns Pharmaceuticals | $6.80 | $18.67 | 174.56% | Buy |
| MREO | Mereo BioPharma Group | $3.40 | $8.00 | 135.29% | Buy |
| DAWN | Day One Biopharmaceuticals | $12.64 | $24.00 | 89.87% | Buy |
| HOOK | HOOKIPA Pharma | $2.13 | $3.00 | 40.85% | Buy |